Annovis Bio promotes Cheng Fang to chief scientific officer

Annovis Bio Inc

ANVS

0.00

Annovis promoted Cheng Fang to chief scientific officer, effective July 1, 2026.
Fang joined in 2021, most recently served as senior vice president of research and development.
She will lead scientific strategy across Alzheimer’s and Parkinson’s programs as lead drug buntanetap moves toward Phase 3 AD topline data.
The role covers translational science, clinical development, biomarker strategy, regulatory interactions, and preparation for a potential NDA submission.
Fang holds a Ph.D. in neuroscience from Penn State, previously held senior roles spanning translational research, clinical development, regulatory strategy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Annovis Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607010800PRIMZONEFULLFEED9755214) on July 01, 2026, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.